Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2022 | CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer

Mascha Binder • 19 Sep 2022
ITOC 2022
Thyroid Cancer

Mascha Binder, MD, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany, discusses the generation of CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mascha Binder

3:59
The selection of PD-L1 escape variants in microsatellite stable metastatic CRC on avelumab treatment
Mascha Binder • 19 Sep 2022
2:29
The prognostic potential of liquid biopsy in advanced HER2 positive esophagogastric adenocarcinoma
Mascha Binder • 19 Sep 2022
4:00
Chemotherapy and immunotherapy: to combine or not to combine?
Mascha Binder • 19 Sep 2022

Related Videos

3:19
Future directions of targeted agents in the treatment of thyroid and neuroendocrine tumors
Enrique Grande • 22 Oct 2023
3:42
AI analysis of TILs in H&E slides to explore immune phenotypes in papillary thyroid cancer
Young Kwang Chae • 4 Jun 2023
2:10
Exploring the new frontier: radionuclide therapy in metastatic prostate cancer
Jeremie Calais • 3 Jun 2023
1:17
Evaluating the genomic landscape of thyroid cancer
Blessie Elizabeth Nelson • 17 Apr 2023
The content of VJOncology is intended for healthcare professionals